Lifeboat Foundation

Now, in an important new resource for the scientific community published today in Nature Biotechnology, researchers in the lab of Neville Sanjana, PhD, at the New York Genome Center and New York University have developed a new kind of CRISPR screen technology to target RNA.

The researchers capitalized on a recently characterized CRISPR enzyme called Cas13 that targets RNA instead of DNA. Using Cas13, they engineered an optimized platform for massively-parallel genetic screens at the RNA level in human cells. This screening technology can be used to understand many aspects of RNA regulation and to identify the function of non-coding RNAs, which are RNA molecules that are produced but do not code for proteins.

By targeting thousands of different sites in human RNA transcripts, the researchers developed a machine learning-based predictive model to expedite identification of the most effective Cas13 guide RNAs. The new technology is available to researchers through an interactive website and open-source toolbox to predict guide RNA efficiencies for custom RNA targets and provides pre-designed guide RNAs for all human protein-coding genes.

Although the majority of the synthetic biology market is concentrated in North America and Europe, the synthetic biology landscape is growing worldwide — with some of the fastest growing areas developing outside of the United States. There are several hotspots — formed when innovation at one company or university lab sparks new spinoffs — that synthetic biology followers should pay close attention to in the coming months and years.

The United Kingdom and Ireland

Among non-US hotspots for synthetic biology, the United Kingdom stands out. While most US universities still lack programs in synthetic biology, they are not hard to come by in the UK. Imperial College London, the University of Warwick, Cambridge University, and the University of Edinburgh are all particularly noteworthy for the depth and breadth of synthetic biology research. And, OpenPlant, a joint initiative between the University of Cambridge, John Innes Centre, and the Earlham Institute, is advancing synthetic biology by engineering the next generation of DNA tools for “smart” crop breeding systems.

Google the word “jugaad,” and you’ll find a plethora of results, from simple dictionary definitions to advice that Western companies should adopt it as part of their practices. Jugaad — a colloquial Hindi, Bengali, and Punjab word — simply means “hack,” and captures the pervasive Indian spirit of finding a low-cost — and sometimes quite resourceful — solution to any problem. If this word doesn’t make one think of entrepreneurship, I don’t know what does.

Indeed, the small-scale biotech facilities scattered all across India, offering products with extremely high adoption rates such as microbial-based biofertilizers, capture the essence of jugaad. In India, finding solutions to the problems at hand is very natural, a way of life, essentially — and any solution, especially an economically sensible one, will be readily adopted. With such a pervasive ideal, India seems like the perfect setting for synthetic biology and biotech-based innovation.

For the first time, scientists used CRISPR treatment inside the human body to treat a patient with genetic blindness.

Life is rife with patterns. It’s common for living things to create a repeating series of similar features as they grow: think of feathers that vary slightly in length on a bird’s wing or shorter and longer petals on a rose.

It turns out the brain is no different. By employing advanced microscopy and mathematical modeling, Stanford researchers have discovered a pattern that governs the growth of brain cells or neurons. Similar rules could guide the development of other cells within the body, and understanding them could be important for successfully bioengineering artificial tissues and organs.

Their study, published in Nature Physics, builds on the fact that the brain contains many different types of neurons and that it takes several types working in concert to perform any tasks. The researchers wanted to uncover the invisible growth patterns that enable the right kinds of neurons to arrange themselves into the right positions to build a brain.

Circa 2016 o.o

The federal government just proposed new rules that would allow researchers to grow human-animal hybrids for research, so long as they can’t think, feel, or breed.

The news did not sit well with Chinese scientists, who are still recovering from the CRISPR baby scandal. “It makes you wonder, if their reason for choosing to do this in a Chinese laboratory is because of our high-tech experimental setups, or because of loopholes in our laws?” lamented one anonymous commentator on China’s popular social media app, WeChat.

Their frustration is understandable. Earlier in April, a team from southern China came under international fire for sticking extra copies of human “intelligence-related” genes into macaque monkeys. And despite efforts to revamp its reputation in biomedical research ethics, China does have slacker rules in primate research compared to Western countries.

If you’re feeling icked out, you’re not alone. The morality and ethics of growing human-animal hybrids are far from clear. But creepiness aside, scientists do have two reasons for wading into these uncomfortable waters.

In a new publication in Nature Plants, assistant professor of Plant Science at the University of Maryland Yiping Qi has established a new CRISPR genome engineering system as viable in plants for the first time: CRISPR-Cas12b. CRISPR is often thought of as molecular scissors used for precision breeding to cut DNA so that a certain trait can be removed, replaced, or edited. Most people who know CRISPR are likely thinking of CRISPR-Cas9, the system that started it all. But Qi and his lab are constantly exploring new CRISPR tools that are more effective, efficient, and sophisticated for a variety of applications in crops that can help curb diseases, pests, and the effects of a changing climate. With CRISPR-Cas12b, Qi is presenting a system in plants that is versatile, customizable, and ultimately provides effective gene editing, activation, and repression all in one system.

“This is the first demonstration of this new CRISPR-Cas12b system for plant genome engineering, and we are excited to be able to fill in gaps and improve systems like this through new technology,” says Qi. “We wanted to develop a full package of tools for this system to show how useful it can be, so we focused not only on editing, but on developing gene repression and activation methods.”

It is this complete suite of methods that has ultimately been missing in other CRISPR systems in plants. The two major systems available before this paper in plants were CRISPR-Cas9 and CRISPR-Cas12a. CRISPR-Cas9 is popular for its simplicity and for recognizing very short DNA sequences to make its cuts in the genome, whereas CRISPR-Cas12a recognizes a different DNA targeting sequence and allows for larger staggered cuts in the DNA with additional complexity to customize the system. CRISPR-Cas12b is more similar to CRISPR-Cas12a as the names suggest, but there was never a strong ability to provide gene activation in plants with this system. CRISPR-Cas12b provides greater efficiency for gene activation and the potential for broader targeting sites for gene repression, making it useful in cases where genetic expression of a trait needs to be turned on/up (activation) or off/down (repression).

Essentially the microchip that heals article turns the normal process of healing into an accelerated way but eventually crispr could be used to make super fast healing and regeneration.

Normal wound healing is a dynamic and complex multiple phase process involving coordinated interactions between growth factors, cytokines, chemokines, and various cells. Any failure in these phases may lead wounds to become chronic and have abnormal scar formation. Chronic wounds affect patients’ quality of life, since they require repetitive treatments and incur considerable medical costs. Thus, much effort has been focused on developing novel therapeutic approaches for wound treatment. Stem-cell-based therapeutic strategies have been proposed to treat these wounds. They have shown considerable potential for improving the rate and quality of wound healing and regenerating the skin. However, there are many challenges for using stem cells in skin regeneration. In this review, we present some sets of the data published on using embryonic stem cells, induced pluripotent stem cells, and adult stem cells in healing wounds. Additionally, we will discuss the different angles whereby these cells can contribute to their unique features and show the current drawbacks.